Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 47

Cited In for PubMed (Select 16896003)

1.

Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma.

Pisani F, Sciuto R, Dessanti ML, Giannarelli D, Kayal R, Rea S, Marchesi F, Marino M.

Exp Hematol Oncol. 2015 Jun 24;4:17. doi: 10.1186/s40164-015-0012-3. eCollection 2015.

2.

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW.

J Clin Oncol. 2015 May 1;33(13):1482-90. doi: 10.1200/JCO.2014.57.5092. Epub 2015 Mar 30.

PMID:
25823738
3.

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, Bourgeois P, Vanderlinden B, van Dongen GA, Everaert H, Vaes M, Bron D.

Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1304-14. doi: 10.1007/s00259-015-3025-6. Epub 2015 Mar 20.

4.

Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.

Chen Q, Ayer T, Nastoupil LJ, Rose AC, Flowers CR.

Value Health. 2015 Mar;18(2):189-97. doi: 10.1016/j.jval.2014.12.017.

PMID:
25773554
5.

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell SM.

Blood. 2015 Feb 5;125(6):992-8. doi: 10.1182/blood-2014-06-583369. Epub 2014 Nov 24.

PMID:
25422100
6.

Adaptive immunity in cancer immunology and therapeutics.

Spurrell EL, Lockley M.

Ecancermedicalscience. 2014 Jul 2;8:441. doi: 10.3332/ecancer.2014.441. eCollection 2014. Review.

7.

Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma.

Sánchez Ruiz AC, de la Cruz-Merino L, Provencio Pulla M.

Ther Adv Hematol. 2014 Jun;5(3):78-90. doi: 10.1177/2040620714532282. Review.

8.

R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.

Friedberg JW, Unger JM, Burack WR, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP, Fisher RI.

Br J Haematol. 2014 Aug;166(3):382-9. doi: 10.1111/bjh.12906. Epub 2014 Apr 18.

PMID:
24749780
9.

The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma.

Kimball AS, Webb TJ.

Mol Cell Pharmacol. 2013 Jan 1;5(1):27-38.

10.

Advances in the treatment of hematologic malignancies using immunoconjugates.

Palanca-Wessels MC, Press OW.

Blood. 2014 Apr 10;123(15):2293-301. doi: 10.1182/blood-2013-10-492223. Epub 2014 Feb 27. Review.

11.

Nanotechnology and drug delivery: an update in oncology.

Jones T, Saba N.

Pharmaceutics. 2011 Apr 14;3(2):171-85. doi: 10.3390/pharmaceutics3020171.

12.

Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management.

Carter Y, Sippel RS, Chen H.

Oncologist. 2014 Jan;19(1):34-43. doi: 10.1634/theoncologist.2013-0237. Epub 2013 Dec 5. Review.

13.

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI.

Clin Cancer Res. 2013 Dec 1;19(23):6624-32. doi: 10.1158/1078-0432.CCR-13-1120. Epub 2013 Oct 15.

14.

Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.

Wagner JY, Schwarz K, Schreiber S, Schmidt B, Wester HJ, Schwaiger M, Peschel C, von Schilling C, Scheidhauer K, Keller U.

Oncotarget. 2013 Jun;4(6):899-910.

15.

Therapy of newly diagnosed follicular lymphoma.

Westin JR, Neelapu SS.

Front Oncol. 2012 Dec 11;2:188. doi: 10.3389/fonc.2012.00188. eCollection 2012.

16.

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI.

J Clin Oncol. 2013 Jan 20;31(3):314-20. doi: 10.1200/JCO.2012.42.4101. Epub 2012 Dec 10.

17.

Management of indolent lymphoma: where are we now and where are we going.

Lunning MA, Vose JM.

Blood Rev. 2012 Nov;26(6):279-88. doi: 10.1016/j.blre.2012.09.004. Epub 2012 Oct 9. Review.

18.
19.

Radioimmunotherapy in mantle cell lymphoma.

Skarbnik AP, Smith MR.

Best Pract Res Clin Haematol. 2012 Jun;25(2):201-10. doi: 10.1016/j.beha.2012.04.004. Epub 2012 May 9. Review.

20.

Immunotherapy for B-cell lymphoma: current status and prospective advances.

Hollander N.

Front Immunol. 2012 Jan 24;3:3. doi: 10.3389/fimmu.2012.00003. eCollection 2012.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk